Lungs News and Research

RSS

Pitt, UPCI researchers' cancer studies presented at AACR meeting

How do certain multiple myeloma treatment drugs cause complications? How does the immune system become dysfunctional due to cancer? How safe is a vaccine that could prevent development of precancerous colon polyps? Those are among the many questions that will be answered by researchers from the University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine during the American Association for Cancer Research 102nd Annual Meeting 2011, April 2 to 6, in Orlando, Fla.

7 Apr 2011

Key enzyme in non-small cell lung cancers could make standard chemotherapy more effective

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented a study at the American Association for Cancer Research's 102nd Annual Meeting 2011 that identifies a key enzyme in non-small cell lung cancers that could potentially make standard chemotherapy more effective against this highly deadly disease.

7 Apr 2011

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

Vitamins, herbs and other dietary supplements are sold as natural alternatives to pharmaceuticals and many people turn to them in an attempt to improve their health. Others seek supplements to lose weight or after hearing that they can help with serious medical conditions.

7 Apr 2011

USPTO issues notice of allowance to Mirna's mir34a patent application

Mirna Therapeutics, Inc. announced today that the United States Patent and Trademark Office has allowed patent claims related to the therapeutic application of the potent tumor suppressor microRNA, mir34a.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Parkinson's disease linked to increased risk of prostate cancer

University of Utah School of Medicine researchers have found compelling evidence that Parkinson's disease is associated with an increased risk of prostate cancer and melanoma, and that this increased cancer risk also extends to close and distant relatives of individuals with Parkinson's disease.

7 Apr 2011

Record number of medicines for various cancers in clinical trials

A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

6 Apr 2011

Novartis' TOBI Podhaler receives Health Canada NOC for Pa treatment in CF patients

Novartis Canada announced today that it has received Health Canada Notice of Compliance for TOBI Podhaler, a fast and convenient inhaled therapy for cystic fibrosis patients aged six and over.

6 Apr 2011

Study: Hookah use may spread among youth in the U.S.

An alternative and harmful form of tobacco use, known as the hookah or water pipe, may be spreading among youth in the United States according to researchers from the University of California, San Diego's Department of Family and Preventive Medicine and San Diego State University. This trend is emerging even as cigarette smoking among high school students is on the decline nationally.

6 Apr 2011

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells. When normal cells are starved for food, they chew up existing proteins and membranes to stay alive. Cancer cells have corrupted that process, called autophagy, using it to survive when they run out of nutrients and to evade death after damage from chemotherapy and other sources.

6 Apr 2011

New stethoscope for nurses from Littmann

A new stethoscope designed especially for nursing professionals has been launched by global technology company 3M. The Littmann Lightweight II S.E. stethoscope has a unique ovoid double-sided chestpiece for better movement around blood pressure cuffs and body contours, making it ideal for listening to blood pressure, chest, bowel, abdominal, heart, lung and breath sounds.

5 Apr 2011

New risk calculator predicts risk of postoperative complications for bariatric surgery patients

A new risk calculator can predict the risk of postoperative complications occurring for individual bariatric surgery patients, according to a study published in the March issue of the Journal of the American College of Surgeons. The risk calculator will help in surgical decision-making and will help patients better understand what they can expect during recovery in order to prepare for a bariatric operation.

5 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

La Jolla acquires GliaMed's novel class of compounds

La Jolla Pharmaceutical Company today announced that it has acquired the rights to a novel class of compounds known as Regenerative Immunophilin Ligands from privately held GliaMed, Inc.

5 Apr 2011

The New England Journal of Medicine publishes positive results from NorthShore's EVEREST II trial

NorthShore University HealthSystem interventional cardiologist, Ted Feldman, MD, presented positive results from the EVEREST II trial, that were concurrently published in The New England Journal of Medicine.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 132 national research and training grants totaling $49,213,000 to 85 institutions nationwide in the second of two grants cycles for 2011.

5 Apr 2011

Serum test can detect lung cancer in non-smokers

A panel of biomarkers appears to be able to identify the presence of lung cancer in the blood samples of people who have never smoked, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

5 Apr 2011

Lungs News and Research

Pitt, UPCI researchers' cancer studies presented at AACR meeting

Key enzyme in non-small cell lung cancers could make standard chemotherapy more effective

Supplements are less well regulated than drugs and may have side effects, drug interactions and toxicities

USPTO issues notice of allowance to Mirna's mir34a patent application

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Parkinson's disease linked to increased risk of prostate cancer

Record number of medicines for various cancers in clinical trials

Novartis' TOBI Podhaler receives Health Canada NOC for Pa treatment in CF patients

Study: Hookah use may spread among youth in the U.S.

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

New stethoscope for nurses from Littmann

New risk calculator predicts risk of postoperative complications for bariatric surgery patients

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

La Jolla acquires GliaMed's novel class of compounds

The New England Journal of Medicine publishes positive results from NorthShore's EVEREST II trial

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

Serum test can detect lung cancer in non-smokers

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News